News

All news

2020-04-02

ACCORD DONATING TWO MILLION TABLETS TO LARGEST COVID-19 TRIAL

Accord Healthcare is proud to announce that it is donating two million tablets of hydroxychloroquine to the largest COVID-19 trial in the world involving 40,000 frontline healthcare workers. The trial, called COPCOV, is led by UK scientists from the University of Oxford, funded by the Wellcome Trust and coordinated by the MORU Tropical Health Network. COPCOV is a large multi-national study researching the prevention of COVID-19 infection using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19, in line with the World Health Organisation’s targeted research priorities.

Dr James Burt, Executive Vice President, Europe and MENA said: “I am extremely proud that Accord is leading the way and playing an important part in the current COVID-19 pandemic. In addition to providing scientific advice, our teams are working around the clock, in challenging times, to manufacture the required hydroxychloroquine and matching-placebo for this vital study.

This is a great demonstration of Accord’s mission to provide essential medicines to people in need, helping to make things better for healthcare professionals on the frontline, patients and society in general.”

To view Accord on LinkedIn please click here.

All news